Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update
Publication Type:Journal Article
Source:Eur J Pharm Sci, Volume 30, Number 2, p.107-12 (2007)
DOI Name (links to online publication)10.1016/j.ejps.2006.11.007
Keywords:Biological Markers/*analysis; Drug Therapy/adverse effects/methods/trends; Drug Toxicity/*prevention; &; control; Humans; Models; Biological
An expert group met in Leiden to review the state-of-the-art in detecting drug-related safety problems and to review the role of biomarkers and modelling techniques. It was clear that new drugs are not necessarily safer than old drugs, despite much larger clinical trial programs. Larger or longer clinical trials may be unfeasible and postmarketing surveillance is not being undertaken systematically enough to ensure safety. Biomarkers could improve drug safety by detecting drug-related signals early but determining whether the biomarker is on the causal pathway to toxicity is difficult. The maturity and utility of safety-related biomarkers varies among target organ systems. A consortium approach to assimilate a large amount of biomarker-related safety signals incorporating this information into mechanism-based models may provide a useful way forward. However no techniques will ensure that drugs are perfectly safe and communication with the public is required to achieve mutual understanding of benefit risk/balance assessments.